Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
9.560 ^USD	+10.14%		+21.94%	+8.39%

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT

Transcript : Vanda Pharmaceuticals Inc., Q4 2024 Earnings Call, Feb 13, 2025

Published on 02/13/2025 at 09:30 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT
03-03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
03-03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
03-03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT
02-27	European Medicines Agency Panel Issues Negative Opinion on Vanda's Schizophrenia Treatment	MT
02-27	Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone	MT
02-27	Ema's CHMP recommended granting a marketing authorisation for Mcombriax	RE
02-25	Vanda Pharmaceuticals Says US FDA Accepts Imsidolimab BLA for Rare Skin Disease	MT
02-25	B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating	MT
02-25	Vanda Pharmaceuticals Announces Fda Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	CI
02-25	Vanda Pharmaceuticals announces FDA acceptance of Biologics License Application filing for Imsidolimab for the treatment of generalized pustular psoriasis	RE
02-23	Top Premarket Gainers	MT
02-23	Vanda Pharmaceuticals Gain Following FDA Approval of Bipolar, Schizophrenia Treatment	DJ
02-23	Vanda Gets FDA Approval for Bysanti in Schizophrenia, Bipolar I Disorder; Shares Up Pre-Bell	MT